Quality of life and impairment in patients with multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 1, 2005, Pages 64-69

  Isaksson, A K ^a   Ahlstrom G ^a   Gunnarsson, L G ^b  

^a ÖREBRO UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISABILITY; EMOTIONAL STABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH SURVEY SHORT FORM 36; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SELF REPORT; SOCIAL STATUS; SUBJECTIVE ESTIMATION OF QUALITY OF LIFE; SYMPTOMATOLOGY; WELLBEING;

ACTIVITIES OF DAILY LIVING; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE;

EID: 10944270694     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.029660     Document Type: Article

References (38)

1. Gill T, Feinstein A. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;24/31:619-26.
2. Benito-Leon J, Morales JM, Rivera-Navarro J, et al. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003;25:1291-303.
3. Freeman J, Hobart J, Langdon D, et al. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:150-6.
4. Nortvedt M, Riise T, Myhr K, et al. Quality of life in multiple sclerosis: measuring the disease effects more. Neurology 1999;53:1098-103.
5. Ford H, Gerry E, Johnson M, et al. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil 2001;23:516-21.
6. Hermann B, Vickrey B, Hays R, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996;25:113-18.
7. Arnoldus JH, Killestein J, Pfennings LE, et al. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler 2000;6:338-42.
8. Freeman JA, Hobart JC, Langdon DW, et al. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:150-6.
9. Nortvedt MW, Riise T, Myhr KM, et al. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler 1999;5:317-22.
10. Schwartz CE, Coulthard-Morris L, Cole B, et al. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol 1997;54:1475-80.
11. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003;216:113-18.
12. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001;57:1870-5.
13. Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003;98:245-55.
14. Myers LW. Immunologic therapy for secondary and primary progressive multiple sclerosis. Curr Neurol Neurosci Rep 2001;1:286-93.
15. Kurtzke J. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
17. World Health Organization. International classification of function, disability and health (ICF). www.who/.int/icidh/011031 (accessed 25 May 2004).
18. Widar M, Ahlström G. Disability after stroke and the influence of long term pain on everyday life. Scand J Caring Sci 2002;16:302-10.
19. Olek M, Dawson D. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Marsden C, ed. Neurology in Clinical Practice. Butterworth-Heinemann, 2000:1431-63.
20. Ware JJ, Sherbourne C. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care 1992;30:473-83.
21. Sullivan M, Karlsson J, Ware EJ. The Swedish SF-36 Health Survey-1. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995;41:1349-58.
22. Sullivan M, Karlsson J, Ware JJ. SF-36 Hälsoenkät: Svensk Manual och Tolkningsguide (Swedish manual and interpretation guide). Göteborg: Sahlgrenska University Hospital, 1994.
23. Sullivan M, Karlsson J. The Swedish SF-36 Health Survey III. Evaluation of criterion- based validity: results from normative population. J Clin Epidemiol 1998;51:1105-13.
24. Kajandi M. Psychiatric and interactional perspective on quality of life. In: Nordenfeldt L, ed. Concepts and measurement of quality of life in health care. Dordrecht: Kluwer Academic, 1994:257-77.
25. Naess S. Quality of life research. Concepts, Methods, and Applications. Oslo: Institute of Applied Social Research, 1987.
26. Hugosson S, Carlsson E, Borg E, et al. Audiovestibular and neuropsychological outcome of adults who had recovered from childhood bacterial meningitis. Int J Pediatr Otorhinolaryngol 1997;42:149-67.
27. Bergemalm PO, Borg E. Long-term objective and subjective audiologic consequences of closed head injury. Acta Otolaryngol 2001;121:724-34.
28. Colton T. Statistics in medicine. Boston: Little, Brown, 1974.
29. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003;9:63-72.
30. Hickey J. Multiple sclerosis. In: Hickey J, ed. The Clinical Practice of Neurological and Neurosurgical Nursing. Philadelphia: Lippincott, 1997.
31. Altman D. Practical statistics for medical research. London: Chapman & Hall, 1991.
32. Sullivan M, Karlsson J. The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol 1998;51:1105-13.
33. Nortvedt M, Riise T, Myhr K, et al. Quality of life as a predictor for change in disability in MS. Neurology 2000;55:51-4.
34. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology 1999;52:63-70.
35. Ahlström G, Gunnarsson L-G, Kihlgren A, et al. Respiratory function, electrocardiography and quality of life in individuals with muscular dystrophy. Chest 1994;106:173-9.
36. Ahlström G. Consequences of muscular dystrophy: Impairment, disability, coping and quality of life. (Dissertation) Acta Universitatis Uppsaliensis, 489. Uppsala, Sweden: Uppsala University, 1994.
37. Lazarus R, Folkman S. Stress, appraisal, and coping. New York: Springer, 1984.
38. Singer M, Hopman W, MacKenzie T. Physical function and mental health in patients with chronic medical conditions. Qual Life Res 1999;8:687-91.